Role of tumor-associated macrophages in cholangiocarcinoma

Pinsheng HAN; Long YANG; Tao CUI; Yamin ZHANG

doi:10.3969/j.issn.1001-5256.2023.02.035

Volume 39 Issue 2

Feb. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(2): 469-473

PDF( 2014 KB)

Role of tumor-associated macrophages in cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2023.02.035

Pinsheng HAN¹,
Long YANG²,
Tao CUI^{3, 4},
Yamin ZHANG^{2
,
,
,}

1.
Clinical Medical College of Tianjin Medical University, Tianjin 300070, China
2.
Department of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin 300192, China
3.
State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin 300000, China
4.
Research Unit for Drug Metabolism, Chinese Academy of Medical Sciences, Beijing 100730, China

Research funding:

Science and Technology Fund of Tianjin First Central Hospital (2019CL01);

CAMS Innovation Fund for Medical Sciences (2019-I2M-5-020);

Tianjin Key Training Project for 'Project + Team' (XC202030)

More Information

Corresponding author: ZHANG Yamin, 13802122219@163.com (ORCID: 0000-0002-7175-8762)
Received Date: 2022-07-02
Accepted Date: 2022-09-05
Published Date: 2023-02-20

Abstract

Abstract

Cholangiocarcinoma (CCA) is a highly malignant biliary tumor with strong invasion and poor prognosis and is insensitive to radiotherapy and chemotherapy. Tumor-associated macrophage (TAM) is an important component of the tumor microenvironment. CCA cells recruit TAM into tumor tissue by releasing cytokines and polarize them into M2 TAM, which promotes the progression of CCA through various mechanisms such as assisting immune escape, promoting tumor cell proliferation, regulating angiogenesis, promoting tumor metastasis, and mediating immune resistance. As an emerging target of tumor immunotherapy, TAM provides new ideas for targeted therapy for CCA. This article reviews the mechanisms of TAM in promoting the progression of CCA and immunotherapy targeting TAM in recent years.
- Bile Duct Neoplasms,
- Macrophages,
- Tumor Microenvironment

FullText(HTML)

References(34)

References

[1]	BERTUCCIO P, MALVEZZI M, CARIOLI G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma[J]. J Hepatol, 2019, 71(1): 104-114. DOI: 10.1016/j.jhep.2019.03.013.
[2]	VALLE J, WASAN H, PALMER DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281. DOI: 10.1056/NEJMoa0908721.
[3]	CASSETTA L, POLLARD JW. Tumor-associated macrophages[J]. Curr Biol, 2020, 30(6): R246-R248. DOI: 10.1016/j.cub.2020.01.031.
[4]	MURRAY PJ. Macrophage polarization[J]. Annu Rev Physiol, 2017, 79: 541-566. DOI: 10.1146/annurev-physiol-022516-034339.
[5]	RHEE I. Diverse macrophages polarization in tumor microenvironment[J]. Arch Pharm Res, 2016, 39(11): 1588-1596. DOI: 10.1007/s12272-016-0820-y.
[6]	ZHOU M, WANG C, LU S, et al. Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target[J]. EBio Medicine, 2021, 67: 103375. DOI: 10.1016/j.ebiom.2021.103375.
[7]	RAGGI C, CORRENTI M, SICA A, et al. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages[J]. J Hepatol, 2017, 66(1): 102-115. DOI: 10.1016/j.jhep.2016.08.012.
[8]	TRIPATHI C, TEWARI BN, KANCHAN RK, et al. Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin[J]. Oncotarget, 2014, 5(14): 5350-5368. DOI: 10.18632/oncotarget.2110.
[9]	CHEN X, SONG E. Turning foes to friends: targeting cancer-associated fibroblasts[J]. Nat Rev Drug Discov, 2019, 18(2): 99-115. DOI: 10.1038/s41573-018-0004-1.
[10]	ZIANI L, CHOUAIB S, THIERY J. Alteration of the antitumor immune response by cancer-associated fibroblasts[J]. Front Immunol, 2018, 9: 414. DOI: 10.3389/fimmu.2018.00414.
[11]	LEONE RD, POWELL JD. Metabolism of immune cells in cancer[J]. Nat Rev Cancer, 2020, 20(9): 516-531. DOI: 10.1038/s41568-020-0273-y.
[12]	HAYES CS, SHICORA AC, KEOUGH MP, et al. Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment[J]. Cancer Immunol Res, 2014, 2(3): 274-285. DOI: 10.1158/2326-6066.CIR-13-0120-T.
[13]	WHITESIDE TL. What are regulatory T cells (Treg) regulating in cancer and why?[J]. Semin Cancer Biol, 2012, 22(4): 327-334. DOI: 10.1016/j.semcancer.2012.03.004.
[14]	VIVIER E, UGOLINI S, BLAISE D, et al. Targeting natural killer cells and natural killer T cells in cancer[J]. Nat Rev Immunol, 2012, 12(4): 239-252. DOI: 10.1038/nri3174.
[15]	HASITA H, KOMOHARA Y, OKABE H, et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma[J]. Cancer Sci, 2010, 101(8): 1913-1919. DOI: 10.1111/j.1349-7006.2010.01614.x.
[16]	PERUGORRIA MJ, OLAIZOLA P, LABIANO I, et al. Wnt-β-catenin signalling in liver development, health and disease[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(2): 121-136. DOI: 10.1038/s41575-018-0075-9.
[17]	LOILOME W, BUNGKANJANA P, TECHASEN A, et al. Activated macrophages promote Wnt/β-catenin signaling in cholangiocarcinoma cells[J]. Tumour Biol, 2014, 35(6): 5357-5367. DOI: 10.1007/s13277-014-1698-2.
[18]	BOULTER L, GUEST RV, KENDALL TJ, et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited[J]. J Clin Invest, 2015, 125(3): 1269-1285. DOI: 10.1172/JCI76452.
[19]	CHEN S, CHEN Z, LI Z, et al. Tumor-associated macrophages promote cholangiocarcinoma progression via exosomal Circ_0020256[J]. Cell Death Dis, 2022, 13(1): 94. DOI: 10.1038/s41419-022-04534-0.
[20]	SUBIMERB C, PINLAOR S, LULITANOND V, et al. Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma[J]. Clin Exp Immunol, 2010, 161(3): 471-479. DOI: 10.1111/j.1365-2249.2010.04200.x.
[21]	HENZE AT, MAZZONE M. The impact of hypoxia on tumor-associated macrophages[J]. J Clin Invest, 2016, 126(10): 3672-3679. DOI: 10.1172/JCI84427.
[22]	SUN D, LUO T, DONG P, et al. M2-polarized tumor-associated macrophages promote epithelial-mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma[J]. J Cell Biochem, 2020, 121(4): 2828-2838. DOI: 10.1002/jcb.29514.
[23]	TECHASEN A, LOILOME W, NAMWAT N, et al. Cytokines released from activated human macrophages induce epithelial mesenchymal transition markers of cholangiocarcinoma cells[J]. Asian Pac J Cancer Prev, 2012, 13(Suppl): 115-118.
[24]	KITANO Y, OKABE H, YAMASHITA YI, et al. Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma[J]. Br J Cancer, 2018, 118(2): 171-180. DOI: 10.1038/bjc.2017.401.
[25]	SICA A, LARGHI P, MANCINO A, et al. Macrophage polarization in tumour progression[J]. Semin Cancer Biol, 2008, 18(5): 349-355. DOI: 10.1016/j.semcancer.2008.03.004.
[26]	EL-GAMAL MI, AL-AMEEN SK, AL-KOUMI DM, et al. Recent advances of colony-stimulating factor-1 receptor (CSF-1R) kinase and its inhibitors[J]. J Med Chem, 2018, 61(13): 5450-5466. DOI: 10.1021/acs.jmedchem.7b00873.
[27]	MACDONALD KP, PALMER JS, CRONAU S, et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation[J]. Blood, 2010, 116(19): 3955-3963. DOI: 10.1182/blood-2010-02-266296.
[28]	PYONTECK SM, AKKARI L, SCHUHMACHER AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression[J]. Nat Med, 2013, 19(10): 1264-1272. DOI: 10.1038/nm.3337.
[29]	YOSHIMURA T. The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally?[J]. Cell Mol Immunol, 2018, 15(4): 335-345. DOI: 10.1038/cmi.2017.135.
[30]	DWYER BJ, JARMAN EJ, GOGOI-TIWARI J, et al. TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression[J]. J Hepatol, 2021, 74(4): 860-872. DOI: 10.1016/j.jhep.2020.11.018.
[31]	LOGTENBERG M, SCHEEREN FA, SCHUMACHER TN. The CD47-SIRPα immune checkpoint[J]. Immunity, 2020, 52(5): 742-752. DOI: 10.1016/j.immuni.2020.04.011.
[32]	VAETEEWOOTTACHARN K, KARIYA R, POTHIPAN P, et al. Attenuation of CD47-SIRPα signal in cholangiocarcinoma potentiates tumor-associated macrophage-mediated phagocytosis and suppresses intrahepatic metastasis[J]. Transl Oncol, 2019, 12(2): 217-225. DOI: 10.1016/j.tranon.2018.10.007.
[33]	SHARPE AH, PAUKEN KE. The diverse functions of the PD1 inhibitory pathway[J]. Nat Rev Immunol, 2018, 18(3): 153-167. DOI: 10.1038/nri.2017.108.
[34]	LOEUILLARD E, YANG J, BUCKARMA E, et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma[J]. J Clin Invest, 2020, 130(10): 5380-5396. DOI: 10.1172/JCI137110.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (669) PDF downloads(67)

Role of tumor-associated macrophages in cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2023.02.035

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Role of tumor-associated macrophages in cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2023.02.035

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content